ArticleCancer chemotherapy and pharmacology2022

A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.

Julia Manzo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.